Maravai LifeSciences Holdings Inc. Class A Common Stock vs Sun Life Financial Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.9 (market cap $977.37M), while Sun Life Financial Inc. Common Stock trades at $78.31 (market cap $43.44B). The key difference: Sun Life Financial Inc. Common Stock is far larger — about 44.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Sun Life Financial Inc. Common Stock pays a 3.47% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Sun Life Financial Inc. Common Stock for 0 Days on average.
| MRVI | SLF | |
|---|---|---|
Market Cap | $977.37M | $43.44B |
Volume | 2,742,564 | 333,821 |
Sector | Health | Financials |
52-Week High | $9.00 | $84.07 |
52-Week Low | $2.83 | $57.60 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $1.08B | $45.17B |
Dividend Yield | — | 3.47% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Sun Life Financial (SLF) trades at $77.87, up 0.69% on the day, reflecting steady momentum. The stock shows consistent earnings beats in recent quarters, with Q3 2026 results pending. Financial health is solid, with a P/E of 18.82 and robust cash flow projections for 2026. Recent strategic moves include expanding disability benefits and forming a reinsurance partnership, signaling growth initiatives.
The outlook for SLF is cautiously optimistic, supported by earnings strength and strategic expansions. Key risks include competitive pressures and macroeconomic volatility. Analyst sentiment is mixed, with a majority hold rating, suggesting potential stability but limited near-term upside. Investors should weigh solid fundamentals against sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Sun Life Financial Inc. is a Canada-based financial services company providing insurance, wealth and asset management, and health solutions for individuals and institutions. Its products span life, health, and disability insurance along with mutual funds and pension asset management, through operations in Canada, US, the United Kingdom, Ireland, and across Asia.
Read more on SLF →